Select Page
Clinical Trial for CMT1A begins in Korea

Clinical Trial for CMT1A begins in Korea

The Hereditary Neuropathy Foundation is excited to share that Helixmith, specializing in gene therapy research for over 20 years, has kicked off its phase I and 2a clinical trial for using VM202 (Engensis) to treat CMT1A. The company is currently headquartered in...